Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma.

Trial Profile

Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Busulfan (Primary) ; Fenretinide (Primary) ; Treosulfan (Primary) ; Zoledronic acid (Primary) ; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Ifosfamide; Melphalan; Mesna; Vincristine
  • Indications Ewing's sarcoma
  • Focus Therapeutic Use
  • Acronyms EWING2008
  • Most Recent Events

    • 19 May 2016 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019 as reported by ClinicalTrials.gov.
    • 19 May 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2019, as reported by ClinicalTrials.gov.
    • 06 Jul 2012 Additional lead trial centre identified as reported by German Clinical Trials Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top